Reported 6 months ago
Eli Lilly has announced a $5.3 billion investment in its new Indiana manufacturing plant, totaling $9 billion, to meet the high demand for its weight-loss and diabetes drugs like Zepbound and Mounjaro. The investment will increase production of active pharmaceutical ingredients for these drugs, which are currently in short supply in the U.S. The company has committed a total of $16 billion to new manufacturing sites since 2020 and expects the Lebanon site to start producing medicines by the end of 2026. Additionally, Lilly plans to add 200 full-time jobs to the Lebanon plant as part of the investment.
Source: YAHOO